-
What are the new drug coverage policies at CVS Health?
CVS Health will update its standard formulary on July 1 to include Novo Nordisk's Wegovy and Saxenda, while Eli Lilly's Zepbound will not be covered. This change is part of CVS's strategy to negotiate better discounts for employers, which may impact patient access to certain medications.
-
How will these changes affect patients using Zepbound?
Patients currently using Zepbound may face complications in accessing their medication due to its exclusion from CVS's formulary. This could lead to increased out-of-pocket costs or the need to switch to alternative medications that are covered.
-
What alternatives are available for patients needing obesity medication?
With the addition of Wegovy and Saxenda, patients looking for obesity medications have new options. Wegovy will also be available at a discounted price for uninsured patients, providing a more affordable alternative for those who may have relied on Zepbound.
-
Why is CVS adding Wegovy and Saxenda to its formulary?
CVS is adding Wegovy and Saxenda to its formulary to enhance its competitive edge in the obesity medication market. This move reflects ongoing negotiations and the need to provide patients with effective treatment options while managing costs.
-
What should patients do if their medication is no longer covered?
Patients whose medications are no longer covered should consult their healthcare provider to discuss alternative treatment options. They may also want to contact CVS Health or their insurance provider for guidance on accessing necessary medications.
-
How do these changes reflect the broader market for obesity medications?
The changes at CVS Health highlight the competitive landscape of the obesity medication market, where companies like Novo Nordisk and Eli Lilly are vying for market share. This competition is leading to price reductions and formulary adjustments, impacting patient access and treatment choices.